About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Blocking Sphingolipid Pathway may Lead to New Treatments for Metabolic Diseases

by Dr. Trupti Shirole on October 18, 2016 at 9:59 PM
Font : A-A+

 Blocking Sphingolipid Pathway may Lead to New Treatments for Metabolic Diseases

Blockage of sphingolipid de novo synthesis pathway (through knockout Serine Palmitoyltransferase, the key enzyme in the pathway) impairs hepatocyte polarity, attenuates liver regeneration after hepatectomy, and promotes tumorigenesis, revealed a new research led by SUNY Downstate Medical Center.

Almost all cell types exhibit some sort of polarity, which enables them to carry out specialized functions. Adherens junctions, which consist of the transmembrane protein cadherin and the intracellular components beta-catenin, alpha-catenin, and actin filaments, initiate cell-cell contacts and maintenance of cell polarity.

Advertisement


Because all cell membranes that define cell boundaries and polarity contain lipid bi-layer structures, the lipid, including sphingolipid, environment could influence polarity, yet the mechanism underlying this remission is unknown.

Importantly, the deficiency significantly reduces sphingomyelin but not other sphingolipids in hepatocyte plasma membrane, and greatly reduces cadherin, the major protein in adherens junctions, on the membrane. The deficiency affects cellular distribution of b-catenin, the central component of the canonical Wnt pathway.
Advertisement

Furthermore, such a defect can be partially corrected by sphingomyelin supplementation in vivo and in vitro. SUNY Downstate's Professor of Cell Biology Xian-Cheng Jiang and Assistant Professor of Surgery Chongmin Huan are co-corresponding authors of the article detailing the research.

Dr. Jiang explained, "This was a seven-year effort and a breakthrough linking sphingolipid-mediated cell junctions and tumorigenesis. Our results, for the first time, show that plasma membrane sphingomyelin-related b-catenin cellular distribution is one the key factors in regulating hepatocyte polarity and tumorigenesis."

Dr. Jiang concludes, "This study also will provide a guide for the development of serine palmitoyltransferase inhibitors, which have a potential for the treatment of metabolic diseases such as diabetes."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
Anemia among Indian Women and Children Remains a Cause of Concern- National Family Health Survey-5
View all
Recommended Reading
News Archive
Date
Category
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Syndrome X 

Most Popular on Medindia

Drug Interaction Checker Diaphragmatic Hernia How to Reduce School Bag Weight - Simple Tips The Essence of Yoga Drug Side Effects Calculator Daily Calorie Requirements Find a Hospital Selfie Addiction Calculator Blood Pressure Calculator Noscaphene (Noscapine)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
ASK A DOCTOR ONLINE

×

Blocking Sphingolipid Pathway may Lead to New Treatments for Metabolic Diseases Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests